Pharma companies may lose licence if drugs fail tests
The ministry is looking to issue a notification shortly that will mandate immediate suspension of product licences of companies found producing 'not of standard quality' (NSQ) drugs by government laboratories, officials said.
The Central Drugs Standard Control Organisation (
CDSCO
) on its part has been deliberating the matter with pharma lobby groups that have raised objections.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Victoria Principal Is Almost 75, See Her Now
Reportingly
Undo
Earlier, the government's technical advisory board on drugs, which is part of CDSCO, had approved taking swift action against such manufacturers.
Live Events
"The board noted that it is very important that once a drug is declared NSQ, the license of such product shall be suspended immediately in public interest unless a satisfactory corrective action and preventive action (CAPA) is submitted by such manufactures. After detailed deliberation, DTAB recommended for the appropriate amendment in the Drug Rules in this regard and the suspension product licence should be revoked only after root cause analysis and corresponding CAPA has been implemented," according to the minutes of a board meeting of the technical advisory body.
"The health ministry and the CDSCO is taking a step forward by taking views of the states and pharma bodies as it would require a notification," said a government official on the condition of anonymity.
However, the pharma lobby groups have raised objections and given representations.
NSQ, "is a global phenomenon, and most of the time, it is due to technical issues without any wrongful intent," the Federation of Pharma Entrepreneurs (FOPE) said in its representation.
In a recent meeting, pharma lobby groups also pointed out that many
government testing laboratories
are facing challenges in following the current standards.
"This has been a long-standing concern. It is also necessary that the NSQ investigation includes a review of records and data from government testing laboratories, as well as GLP compliance by the Drugs Inspector," a member of a lobby group opined.
"It has been found that in many cases, samples declared NSQ by government labs, when challenged and tested by CDL Kolkata, have been declared as Standard Quality by CDL Kolkata, which is an appellate laboratory," the person said.
Drug makers also emphasised that more than suspending licenses, it is crucial to strengthen the "recall mechanism".
FOPE urged a proper impact analysis given the sensitivity of the matter.
"We fear it may lead to malpractices in the profession, and genuine manufacturers with investments of hundreds of crores in plant setup, product development, technical team development, brand development, business development, and goodwill, may be adversely impacted if actions like the suspension of product permission are taken without proper investigation," the lobby group said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
14 minutes ago
- Time of India
Ayushman Arogya Mandir in Maoist-hit Bijapur bags National Quality Tag with 96.4% score
RAIPUR: In a remarkable achievement from one of Chhattisgarh's remotest and Maoist-affected districts, the Ayushman Arogya Mandir in Tumnar block, Bijapur district, has secured the prestigious National Quality Assurance Standard (NQAS) certification with a 96.4% score, highlighting the government's commitment to strengthening primary healthcare even in conflict-hit tribal regions. The health centre's excellence across preventive to emergency services under the Ayushman Bharat scheme sets a benchmark for quality care in underserved areas. State Health Minister Shyam Bihari Jaiswal lauded the dedication of healthcare workers and termed it a proud moment for Bijapur, reinforcing the state's resolve to ensure equitable and accessible health services across all geographies. National-level experts conducted a thorough inspection for the NQAS evaluation, assessing the health centre's services, infrastructure, record management, hygiene, and patient care quality. The Ayushman Arogya Mandir Tumnar demonstrated excellence across various domains, including preventive, promotive, curative, rehabilitative, and palliative care. This accomplishment establishes the Ayushman Arogya Mandir Tummar as a model for healthcare services in the region. The Ayushman Arogya Mandir Tummar has expanded its services to include non-communicable diseases, mental health, eye care, geriatric care, and emergency services, which were previously available only at the district level. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like One of the Most Successful Investors of All Time, Warren Buffett, Recommends: 5 Books for Turning... Blinkist: Warren Buffett's Reading List Click Here Undo This centre has been a frontrunner in delivering comprehensive health services under the Ayushman Bharat scheme. State Health Minister Shyam Bihari Jaiswal stated that the NQAS certification for Ayushman Arogya Mandir Tummar is a moment of pride for Bijapur district. He attributed this success to the dedication and collaborative efforts of the healthcare workers. The minister affirmed the government's goal of providing high-quality healthcare services to every citizen in the state, calling this achievement a significant step in that direction.
Time of India
29 minutes ago
- Time of India
New Coca-Cola in Japan claims to promote weight loss-- Here's how it is different
In Japan, where the population is steadily aging, the market is shifting in ways that reflect the needs of an older demographic. Consumer habits are no longer driven purely by taste or trend, but by long-term wellness and health considerations. One of the most well-known global beverage brands, Coca-Cola, is not sitting idly in the face of this change. It's moving forward with an unexpected twist. It has come up with a drink that blends the familiar flavour of cola with ingredients that claim to support better digestion and fat management. Japan's increasing demand for functional foods and beverages has inspired the company to enter the health-conscious space with something new. What is Coca-Cola Plus ? Coca-Cola Plus is a product aimed squarely at older consumers who want to enjoy cola but without the usual health risks tied to sugary sodas. While Coca-Cola has released diet variants before, this new drink is a unique addition to health to the mix. So, what makes Coca-Cola Plus stand out? As Japan's population grows older, companies are finding ways to meet the unique health needs of their consumers. Coca-Cola Japan has introduced Coca-Cola Plus, a sugar-free, calorie-free soft drink that claims to help block fat absorption and reduce blood triglyceride levels when consumed with meals. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo How is it different from the usual Coca-Cola? Unlike traditional diet colas, Coca-Cola Plus is being marketed not just as a "less harmful" alternative, but as a drink that might actually benefit your health. According to Coca-Cola Japan, 'drinking one bottle each day along with meals will both reduce the absorption of fat from the food and moderate the levels of triglycerides in the blood following the meal.' It contains a special dietary fibre Each bottle contains five grams of indigestible dextrin, a type of dietary fibre, along with other added fibres. These components are said to assist digestion and help reduce fat absorption during meals. However, this isn't a drink you can sip on all day. Coca-Cola Plus has a recommended usage: to consume one bottle per day during meals, ideally split into three 150ml servings. The company claims that this routine use can lead to a seven per cent reduction in triglyceride levels when compared to consuming a regular diet cola, as stated on the Coca-Cola Plus website. While the idea of a 'healthy Coke' might sound too good to be true, Coca-Cola is being careful not to overpromise. Rather than labelling it a health drink, they refer to it as a Tokuho Cola. In Japanese, Tokuho stands for Tokutei Hokenyo Shokuhin, which translates to 'Food for Specified Health Uses', a classification for products that provide health benefits but haven't gone through the full process required to be considered medical-grade health food. This cautious but clever labelling allows Coca-Cola to market the drink to health-conscious adults without running foul of regulatory standards. It's especially targeted toward consumers over 40 who still enjoy the taste of cola but are looking for safer, waistline-friendly options.
Time of India
an hour ago
- Time of India
Shubhanshu Shukla's space research could transform diabetes care on Earth
Indian astronaut Shubhanshu Shukla is currently aboard the International Space Station, having launched on June 25, 2025, as part of the Axiom Mission 4 (Ax-4). He is involved in pioneering research aimed at transforming how diabetes is monitored and managed in space. In collaboration with Axiom Space and Burjeel Holdings, the experiment focuses on testing Continuous Glucose Monitors (CGMs) and insulin technologies in microgravity. Known as the "Suite Ride" project, this study could pave the way for safer space travel for people with diabetes and also bring new solutions to diabetes care on Earth, especially in remote or underserved areas. With global diabetes cases on the rise, the mission holds promise for both space medicine and everyday healthcare. What the 'Suite Ride' project of Axiom-4 is doing in space The Suite Ride project is testing the use of CGMs, devices that track blood glucose levels in real time, during spaceflight. One or more astronauts on the Ax-4 mission are wearing CGMs for the full two-week duration. The devices are sending data back to Earth to evaluate their accuracy and stability in microgravity. Insulin pens were also sent to the International Space Station, although the astronauts are not using them. The goal is to see how well insulin maintains its potency in space. Blood samples are being collected and analyzed with specialized equipment, all provided by Burjeel Holdings, to compare results and validate the technology. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 21st Century Skills Start with Confident Communication Planet Spark Learn More Undo Why microgravity offers a unique research opportunity Microgravity creates a different physiological environment, allowing scientists to study the human body in ways that are not possible on Earth. Changes in fluid distribution, muscle mass, and sleep cycles may influence how the body regulates blood sugar and responds to insulin. This could help researchers identify new markers of insulin resistance and understand diabetes at a deeper level. The research also builds on previous findings from missions like Galactic 07, which showed that commercial insulin pens can function in space within international medical standards. How this could change lives on Earth While the long-term goal is to make it possible for astronauts with diabetes to join space missions safely, the benefits of this research are equally valuable on Earth. If CGMs and insulin storage solutions can work reliably in space, they can be adapted for use in harsh or remote locations such as deserts, oil platforms, and rural clinics. Dr. Mohammad Fityan, Chief Medical Officer at Burjeel Holdings, explained that space serves as a testing ground for technologies that could enhance healthcare delivery in low-access regions. With diabetes rising rapidly in areas like the MENA region, where it is expected to increase by 87 percent by 2045, there is a growing need for innovation. What comes next in the research timeline After the mission concludes, researchers will study the collected data to assess how CGMs and insulin performed under space conditions. If the findings are promising, future missions may include astronauts with non-insulin-dependent Type 2 diabetes, followed by those with insulin-dependent diabetes. Dr. Mike Harrison from Axiom Space said this mission is not just about scientific progress in orbit. It is about improving healthcare access on Earth and making space more inclusive for people with chronic conditions. The success of this project could help rewrite the rules of both diabetes care and human spaceflight, bringing us closer to a world where health challenges no longer limit the possibilities of exploration.
